MASLD is related to impaired alcohol dehydrogenase (ADH) activity and elevated blood ethanol levels: Role of TNFα and JNK

Redox Biol. 2024 May:71:103121. doi: 10.1016/j.redox.2024.103121. Epub 2024 Mar 12.

Abstract

Elevated fasting ethanol levels in peripheral blood frequently found in metabolic dysfunction-associated steatohepatitis (MASLD) patients even in the absence of alcohol consumption are discussed to contribute to disease development. To test the hypothesis that besides an enhanced gastrointestinal synthesis a diminished alcohol elimination through alcohol dehydrogenase (ADH) may also be critical herein, we determined fasting ethanol levels and ADH activity in livers and blood of MASLD patients and in wild-type ± anti-TNFα antibody (infliximab) treated and TNFα-/- mice fed a MASLD-inducing diet. Blood ethanol levels were significantly higher in patients and wild-type mice with MASLD while relative ADH activity in blood and liver tissue was significantly lower compared to controls. Both alterations were significantly attenuated in MASLD diet-fed TNFα-/- mice and wild-type mice treated with infliximab. Moreover, alcohol elimination was significantly impaired in mice with MASLD. In in vitro models, TNFα but not IL-1β or IL-6 significantly decreased ADH activity. Our data suggest that elevated ethanol levels in MASLD patients are related to TNFα-dependent impairments of ADH activity.

Keywords: Alcohol dehydrogenase; Alcohol metabolism; Steatotic liver disease; Tumor necrosis factor alpha; c-Jun N-terminal kinase.

MeSH terms

  • Alcohol Dehydrogenase* / genetics
  • Alcohol Dehydrogenase* / metabolism
  • Alcohol Drinking
  • Animals
  • Ethanol / adverse effects
  • Fatty Liver*
  • Humans
  • Infliximab / pharmacology
  • Mice
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Alcohol Dehydrogenase
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Ethanol